December 26, 2024 06:49 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Boat capsizes off Calangute Beach in Goa; 1 killed, 20 rescued | Canada announces change to immigration system, likely to impact Indians seeking permanent residence | Azerbaijan Airlines tragedy: 32 passengers rescued, flight attempted several emergency landing before crashing | Man sets himself on fire near Parliament building; locals, police rush him to hospital | Azerbaijan Airlines passenger plane enroute to Russia with over 70 people onboard crashes in Kazakhstan | Atishi will be arrested in fake case, claims Arvind Kejriwal after Delhi govt disowns health and women's schemes | Delhi govt departments disown Arvind Kejriwal's major poll promises, AAP chief reacts | 'Our nation will always be grateful to him': PM Modi writes article in tribute to Atal Bihari Vajpayee on his birth centenary | Syria: Christmas tree set on fire by suspected 'Islamists', Christians protest | Pakistan strikes TTP camps in Afghanistan, Taliban government claims civilians killed
Glenmark Life Sciences Limited initial public offer to open on July 27

Glenmark Life Sciences Limited initial public offer to open on July 27

Jul 21, 2021, at 11:04 pm

Kolkata: Glenmark Life Sciences Limited, a manufacturer of active pharmaceutical ingredients, plans to open its Initial Public Offering (“Offer”) on July 27, 2021.

Glenmark Pharma receives ANDA approval for Fingolimod Capsules, 0.5 mg

Glenmark Pharma receives ANDA approval for Fingolimod Capsules, 0.5 mg

Jun 19, 2020, at 04:44 pm

Mumbai/UNI:  Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

May 12, 2020, at 07:55 pm

MUMBAI/PRNewswire -- Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India's drug regulator DCGI in late April. Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India. Favipiravir is a generic version of Avigan® of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July/August 2020.